Apnimed, Inc.

Nasdaq: APMD

Day 71 public/EARLY PUBLIC/IPO Jul 31, 2026/Pharmaceutical Preparations

$18.52

▲ 0.30 (+1.65%)

LIVE

updated 15h ago

Intelligence Core

MONITORING

No new filings in 72 h · watching for the next event

Current missionThesis Test · Day 31–90

Test the initial thesis against the first earnings, guidance and execution.

Focus

EarningsGuidanceExecutionInstitutional changes

STRENGTHENINGFORMING THESIS…Intelligence score DERIVED

/ 100

Confidence82%

CURRENT THESIS INTERPRETED

Apnimed, Inc. exhibits a fundamentally sound profile for an early-public company, supported by reported revenue, profitability, and balance sheet cash. High institutional and narrative scores backed by multiple SEC filings and insider forms indicate active market engagement.

Momentum

Price · since IPOLIVE

Yahoo · 50 pts

H $32.55L $18.04Last $18.52

Current ThesisINTERPRETEDLIVE

Why

+Reported revenue and profitability according to SEC XBRL fundamentals
+Cash on the balance sheet providing operational runway
+Active institutional backing indicated by two Schedule 13D/13G filings

Risks

−Newly public status under 90 days with heightened early-stage volatility
−Operating within the clinical-stage pharmaceutical sector
−Momentum signal sits at a neutral 53

Catalysts

→Ongoing regulatory and clinical disclosures via 8-K filings
→Further institutional accumulation evidenced by SEC ownership updates

Current Thesis

Company Web Research · Official DomainVIEW ONLY

https://apnimed.com

VIEW-ONLY

Visit

LIVE · SANDBOXED

Resolving official website…

Research EnvironmentLIVE

Research environment · $APMDSEC · market · news

22 evidence items|newest evidence 3d ago

Core activity · newest firstreal events · view-only

0s agoSCOREDERIVEDIntelligence score 67/100 recomputed from 5 rule-based signals.via Deterministic scoreDERIVED

0s agoSTATECore MONITORING · No new filings in 72 h · watching for the next event. Mission: Thesis Test.via Intelligence Core

15h agoOBSERVATIONVERIFIEDLast price $18.52 · +1.65% on the day.via Finnhub quoteVERIFIED

3d agoEVIDENCEBank of America Puts These 2 Under-the-Radar IPO Stocks on Its Buy Listvia Yahoo · tier 3, cross-check 7d agoEVIDENCEApnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)via Yahoo · tier 3, cross-check 17d agoEVIDENCEWas Moderna Stock's Cancer Vaccine Run Visible In Advance?via Yahoo · tier 3, cross-check Sep 8, 2026EVIDENCEVERIFIEDForm 8-K filed · 8-K.via SEC EDGARVERIFIED Sep 8, 2026EVIDENCEVERIFIEDForm 10-Q filed · 10-Q.via SEC EDGARVERIFIED Sep 8, 2026EVIDENCEVERIFIEDForm S-8 filed · S-8.via SEC EDGARVERIFIED Aug 7, 2026EVIDENCEVERIFIEDForm SCHEDULE 13G filed.via SEC EDGARVERIFIED Aug 6, 2026EVIDENCEVERIFIEDForm SCHEDULE 13G filed.via SEC EDGARVERIFIED

Evidence · SEC filing timelineVERIFIED

Filed	Form	Document	Source
2026-09-08	S-8	S-8	SEC ↗
2026-09-08	10-Q	10-Q	SEC ↗
2026-09-08	8-K	8-K	SEC ↗
2026-08-07	SCHEDULE 13G	Apnimed, Inc.	SEC ↗
2026-08-06	SCHEDULE 13G	Apnimed, Inc.	SEC ↗

VERIFIEDfrom a primary sourceDERIVEDcomputed by rulesINTERPRETEDreasoned from evidence

Assembled 0s ago · every panel labelled live or simulated · no fabricated metrics